A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer.
Jager
W
W
Department of Obstetrics and Gynaecology, Friedrich Alexander University, Erlangen, Germany.
Sauerbrei
W
W
Beck
E
E
Maassen
V
V
Stumpfe
M
M
Meier
W
W
Kuhn
W
W
Janicke
F
F
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016879:Salvage Therapy; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D017211:Treatment Failure; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D017329:Triptorelin Pamoate; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone